AVROBIO Inc. (NASDAQ: AVRO) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We hosted a doc call last week with a leading expert in the field of stem cell and gene therapy to discuss AVRO’s ex-vivo gene therapy approach, including use of conditioning regimen. Bottom line: AVRO’s ex-vivo approach may hold important advantages in the context of lysosomal storage disorders, including a more “systemic effect” compared to AAV, and the potential to circumvent antibody formation. Busulfan conditioning is very tolerable, avoiding important side effects of allogenic transplantation such as GVHD, and the need for long-term immune suppression, while also requiring less hospitalization time.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About AVROBIO Inc.
AVROBIO’s mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. The company aims to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. AVRO’s clinical-stage programs include Fabry disease, Gaucher disease and cystinosis, and the company is also advancing a program in Pompe disease. AVROBIO is powered by the plato™ gene therapy platform, its foundation designed to scale gene therapy worldwide. The company is headquartered in Cambridge, Massachusetts, with an office in Toronto, Ontario. For additional information, visit www.avrobio.com
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.